After obtaining this Master’s degree in Biology and Health Science at Lille University in 2022, Nathan Laneret has just begun a PhD thesis under the supervision of Pr. RA Toillon and Dr. Nathalie Maubon thanks to ANRT fundings (CIFRE). Through this collaboration between the Cellular Plasticity and Cancer team from Canther Lab Read more…
It is a pleasure to announce that HCS Pharma has a new collaborative project dealing with Inflammasome et ion channels Team of OncoLille (PHYCELL Lab, INSERM U1003) in the frame of colon cancer, thanks to France Relance plan and Region Hauts-de-France. This project has started in October 2022 for 2 Read more…
The congress of European Society of Toxicology In Vitro (ESTIV) took place from 21st to 25th November 2022. This congress is focus on the alternative methods to animal testing, including both in silico and in vitro modeling. After a nice opening ceremony with a flamenco show, the scientific program begun Read more…
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
Our Project Leader in in vitro pharmacology Méryl Roudaut will present his presentation entitled “A single procedure to generate functional hiPSCs-derived liver organoids – Towards an innovative tools suitable for drug screening” during the session: Early Stage Researcher Session I (Tuesday, November 22nd, 2022). Abstract #165: We previously showed that Read more…
We are pleased to participate to the 21st International Congress of the European Society of Toxicology In Vitro (ESTIV 2022), which will take place in Barcelona-Sitges, Spain, from 21st to 25th November 2022. Our project Leader in in vitro pharmacology Véronique De Conto will present her poster entitled “In vitro microenvironment modifies the neurotoxic Read more…
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
We are glad to announce the arrival of Gaspard in our team! Gaspard Delpouve obtained his Diploma of Advanced Technician in Biotechnologies in Lille in 2018, and in 2019 he passed a Bachelor’s degree in health biotechnologies at the University of Nantes. During his studies he completed several internships in Read more…
This is the end of the 6-month internship of Natacha in HCS Pharma, about the microenvironment modifications in Parkinson’s disease. Indeed, in vivo studies in the literature showed that the neuronal death in Parkinson’s disease involved Extracellular Matrix (ECM) modifications, including an increase in some components like collagen and a Read more…
Our project director Elodie is participating to EUSAAT congress in Linz (Austria) this week, the European Congress on Alternatives to Animal Testing. She will have the pleasure to present our work aiming at bridging the gap between in vivo and in vitro situations by taking into account the extracellular matrix Read more…
The Federation of European Neuroscience Societies (FENS) forum 2022 took place in Paris, from 9 to 15 July. This event gathers nearly 8,000 neuroscientists from 92 countries. Twenty-two plenary and special lectures were given in 8 conferences room, about various topics in neurosciences, like brain imaging methods, brain development (synapse Read more…
Our project leader in in vitro pharmacology Veronique De Conto will be present to the Federation of European Neurosciences Societies (FENS) congress, from 9 to 13 July in Paris. She will present a poster about the importance of microenvironment in cerebral in vitro models for phenotypic screening, in the frame Read more…
Elodie Vandenhaute (our project director), Véronique De Conto (our project leader in in vitro pharmacology) and Natacha Perrin (our trainee in neurosciences) were present at the annual SCMC (Société Cerveau et Maladies Cérébrovasculaires – The French Brain and Cerebrovascular Diseases Society) congress, which took place on the 16th of June Read more…
To treat brain disease is a challeging purpose, since the brain is protected by a barrier made by of tightly-joined endothelial cells of the cerebral microvessels, called the blood–brain barrier (BBB). To improve this route to reach the central nervous system, several strategies have been developed. Among them, researchers try Read more…
It was a pleasure to be invited by the french association France Immersive Learning in the meeting “Immersive technology in health”. We presented our own uses of VR (virtual reality) and AR (augmented reality) in two different domains. First, we used AR for the installation of our robotic platform, in Read more…
The Extracellular Matrix (ECM) is a major component of all the organs. This dynamic structure is involved not only in cell adhesion, but also in physiological processes, including cell differentiation, migration, and maturation, tissue homeostasis, biochemical signal retention and mediation, and growth factors’ retention. Moreover, the ECM can be abnormally Read more…
We are pleased to welcome Natacha Perrin in our laboratory for a 6-month internship. Natacha is currently in last year of engineering school in Polytech Clermont. This year, in parallel of her initial formation, she also did a double degree in pharmacy. During her studies, she had the opportunity to Read more…
Yesterday, the 11th of April, was the World Parkinson’s Day. On this occasion, HCS pharma would like to inform you about this disease and its work for new drug discovery. What is Parkinson’s disease? It is the second most common neurodegenerative disease after Alzheimer’s disease. It is attributed to a Read more…
Increased ExtraCellular Matrix (ECM) stiffness is a common process in many cancers (Pickup et al, 2014). This process influences the behaviour of cancer cells in the tumour microenvironment. The accumulation of ECM in the stroma is mainly due to a high production of ECM molecules by TGF-β(Transforming Growth Factor-beta) -stimulated Read more…
The extracellular matrix (ECM) is the non-cellular component of tissue. Its is mainly composed of structural and adhesion molecules, such as hyaluronic acid, collagene, proteoglycans, fibronectin, elastin, although its specific composition and structure vary between different tissues. It is a dynamic structure, which is involved not only in the cell Read more…
Scanning Electron Microscopy (EM) has been an indispensable tool for Biological sciences. A great challenge was propelled by the need to find methods to better preserve and analyze structures at a state closest to the native state. With BIOMIMESYS® hydroscaffold technology, we have developed a new method to use SEM Read more…
HCS Pharma était présent au Workshop OoC pour une création et une structuration de la filière, organisé par Biovalley à l’Institut Pierre-Gilles de Gennes (Paris). Nous sommes très heureux d’avoir pu sponsoriser l’événement, mais aussi tout simplement d’y avoir participé – en présentiel – et de pouvoir discuter avec des chercheurs Read more…
How to make in vitro models predictive of in vivo conditions? Dynamic models hold promise for future predictive microphysiological systems (MPS). By combining BIOMIMESYS® as an ECM surrogate for 3D culture, and hiPSC-derived cells, these dynamic microfluidic systems will revolutionize the field, reproducing human tissues and predict human outcomes.